Suchergebnisse - "Nguyen, Bach"

PubPharm (9)

1

Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection : A pooled analysis

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2018

von Asselah, T. | Reesink, H. | Gerstoft, J. | +10

2

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B) : two randomised, phase 2, open-label trials

enthalten in: The lancet. Gastroenterology & hepatology | 2017

von Lawitz, E. | Buti, M. | Vierling, J. | +26

CommentIn: Lancet Gastroenterol Hepatol. 2017 Nov;2(11):771-772. - PMID 28802817

3

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A) : two randomised, phase 2, open-label trials

enthalten in: The lancet. Gastroenterology & hepatology | 2017

von Gane, E. | Pianko, S. | Roberts, S. | +28

CommentIn: Lancet Gastroenterol Hepatol. 2017 Nov;2(11):771-772. - PMID 28802817

4

Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders : A Phase III Study

enthalten in: Hepatology (Baltimore, Md.) | 2017

von Hézode, C. | Colombo, M. | Bourlière, M. | +16

5

Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease : clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial

enthalten in: The lancet. Gastroenterology & hepatology | 2017

von Bruchfeld, A. | Roth, D. | Martin, P. | +12

CommentIn: Lancet Gastroenterol Hepatol. 2017 Aug;2(8):544-546. - PMID 28691680

6

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study) : a combination phase 3 study

enthalten in: Lancet (London, England) | 2015

von Roth, D. | Nelson, D. | Bruchfeld, A. | +16

CommentIn: Lancet. 2015 Oct 17;386(10003):1514-5. - PMID 26456906

7

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION) : a non-randomised, open-label trial

enthalten in: The lancet. HIV | 2015

von Rockstroh, J. | Nelson, M. | Katlama, C. | +16

ErratumIn: Lancet HIV. 2015 Aug;2(8):e316

8

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection : A Randomized Trial

enthalten in: Annals of internal medicine | 2015

von Zeuzem, S. | Ghalib, R. | Reddy, K. | +11

9

2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects

enthalten in: Journal of medicinal chemistry | 2009

von Degoey, D. | Grampovnik, D. | Flentge, C. | +18

1
[1]